This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): T487
Description: T487’s putative mechanism of action includes chemokine receptor inhibition. Such action at the level of lymphocytes can provide pharmacological anti-inflammatory action. Tularik initially hopes to develop T487 in rheumatoid arthritis and psoriasis, with potential future investigation in inflammatory bowel disease. A wealth of preclinical studies supports this strategy, but substantive peer-reviewed publications regarding this specific compound are currently unavailable.
Deal Structure: In 1999, Tularik and ChemoCentryx partnered to develop T487. Tularik retains worldwide commercialization rights; ChemoCentryx receives royalties and milestone payments.
Amgen acquired T487 on August 13, 2004 through Amgen's acquisition of Tularik.
Partners: ChemoCentryx, Inc.
Additional information available to subscribers only: